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 SUMMARY STATEMENT 
Obesity, a co-morbidity for stroke, affected the acute metabolic and inflammatory 
response to stroke, highlighting the importance of considering comorbidities in 
preclinical stroke research, especially when identifying biomarkers. 
 
ABSTRACT 
Obesity is an independent risk factor for stroke, though several clinical studies have 
reported that obesity improves stroke outcome. Obesity is hypothesised to aid 
recovery by protecting against post-stroke catabolism. We therefore assessed 
whether obese mice had an altered metabolic and inflammatory response to stroke. 
Obese ob/ob mice underwent 20 min middle cerebral artery occlusion and 24 h 
reperfusion. Lipid metabolism and expression of inflammatory cytokines were 
assessed in the plasma, liver and adipose tissue. The obese-specific metabolic 
response to stroke was assessed in plasma using non-targeted UPLC-MS 
metabolomics coupled with univariate and multivariate analysis. Obesity had no 
effect on the extent of weight loss 24 h after stroke but affected the metabolic and 
inflammatory responses to stroke, predominantly affecting lipid metabolism. 
Specifically, obese mice had increases in plasma free fatty acids and expression of 
adipose lipolytic enzymes. Metabolomics identified several classes of metabolites 
affected by stroke in obese mice, including fatty acids and membrane lipids 
(glycerophospholipids, lysophospholipids and sphingolipids). Obesity also featured 
increases in inflammatory cytokines in the plasma and adipose tissue. Overall these 
results demonstrate that obesity affected the acute metabolic and inflammatory 
response to stroke and suggest a potential role for adipose tissue in this effect. 
These findings could have implications for longer-term recovery and also further 
highlight the importance of considering comorbidities in preclinical stroke research, 
especially when identifying biomarkers for stroke. However, further work is required 
to assess whether these changes translate into long-term effects on recovery. 
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 INTRODUCTION 
Obesity is a major health problem worldwide that is characterised by excessive fat 
accumulation, disruption of normal metabolic processes, and a state of chronic low-
level inflammation. During obesity, adipocytes become stressed due to their energy 
storage capacity being exceeded, leading to adipose tissue inflammation. Rather 
than being simply a passive energy store, adipose tissue can release a wide variety 
of signalling molecules termed adipokines. Inflammation within the adipose tissue 
therefore leads to the release of pro-inflammatory mediators and adipokines into the 
circulation. Besides having an established role in immune regulation and energy 
balance, adipokines have been found to regulate an expanding array of physiological 
functions, including haemostasis, lipid and glucose metabolism, blood pressure, 
insulin sensitivity, and angiogenesis (Guri and Bassaganya-Riera, 2010; Trayhurn 
and Wood, 2005). Alterations in adipokine release may therefore affect the function 
of other organs important for metabolism, for example the liver.  
Although being obese can result in several conditions that are associated with 
increased stroke risk including hypertension, diabetes and high cholesterol, obesity 
has now been identified as an independent risk factor for stroke (Strazzullo et al., 
2010). However, some epidemiological studies in patients have reported a protective 
effect of obesity on stroke outcome, including reduced long-term mortality and 
improved functional recovery (Doehner et al., 2013; Vemmos et al., 2011). This so-
called ‘obesity paradox’ may potentially be explained by design of the 
epidemiological studies, including complications arising from how obesity is 
measured, age, type and severity of stroke, and study design (Haley and Lawrence, 
2016a). A biological hypothesis that has been proposed to explain the obesity 
paradox is that obesity may protect against the metabolic consequences of stroke 
(Scherbakov et al., 2011). 
Weight loss after stroke is a common clinical observation and metabolic status 
post-stroke is an important determinant of outcome, with undernourishment 
worsening functional recovery and survival (FOOD Trial Collaboration, 2003). 
Impaired feeding behaviour and inactivity due to post-stroke paresis are thought to 
contribute to post-stroke weight loss and recommendations for dietary support of 
patients have been established (Lim and Choue, 2013). However, in both patients 
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 and animals, stroke may also have more immediate and direct effects on energy 
balance via other more rapid mechanisms. Stroke results in an inflammatory 
response within the first 24 h at the site of ischaemia, systemically, and within 
peripheral organs (Denes et al., 2010a). This response involves induction of 
inflammatory cytokines such as interleukin-6 (IL-6), and the chemokines CCL2 
(MCP-1) and CXCL1 (KC). Inflammatory cytokines have been implicated in the 
pathogenesis of cachexia, a condition featuring loss of lean and adipose tissue 
weight due to hypermetabolism (Kotler, 2000). Activation of the hypothalamic-
pituitary-adrenal (HPA) axis is also a feature of stroke that may promote weight loss 
through enhanced sympathetic signalling (Fassbender et al., 1994; Mitchell, 1997). 
The resulting increase in catabolic drive can lead to a loss of adipose and muscle 
mass, potentially leading to a worse functional outcome due to a loss of muscle 
function in patients (Scherbakov and Doehner, 2011). Similar losses of muscle mass 
after stroke have been reported in mice (Desgeorges et al., 2015; Springer et al., 
2014). Changes in metabolism may therefore have an important role to play post-
stroke and potentially impact on pathophysiology and outcome. 
Despite the importance of metabolic status in patient outcome, the metabolic 
response to stroke has undergone little preclinical or clinical investigation. Therefore, 
the study of global metabolism to understand metabolic differences associated with 
stroke and the influence of obesity on outcome is an important research area. 
Metabolomics is the holistic study of low molecular weight chemicals (metabolites) in 
biological systems. Metabolites are important biochemicals as they act as precursors 
for the synthesis of other biochemical (e.g. proteins, RNA, DNA) and cellular 
structures (e.g. cell walls). As metabolites are the substrates and by-products of 
cellular metabolism the quantitative collection of metabolites (defined as the 
metabolome) provides a sensitive and dynamic phenotypic snapshot of human 
health and disease (Dunn et al., 2011a; Patti et al., 2012). This phenotypic snapshot 
can be applied to understand pathophysiological processes or to identify biomarkers 
associated with disease risk, onset, progression and treatment. Recent studies in 
animal models and humans have applied metabolomic approaches to understand 
the molecular pathophysiology of stroke and have highlighted specific important 
areas of metabolism. These include specific changes in amino acids, fatty acids, 
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 sphingolipids, and lysophospholipid species (Gao et al., 2013; Jové et al., 2015; 
Kimberly et al., 2013; Liu et al., 2015; Sheth et al., 2015; Zhu et al., 2015). 
The aim of this study was to assess how the acute metabolic and 
inflammatory responses to stroke were affected by obesity. In obese mice prior to 
and 24 h post-stroke we assessed lipid metabolism and the expression of 
inflammatory mediators in metabolically active organs. The plasma metabolite profile 
was then assessed using non-targeted ultra-high performance liquid 
chromatography-mass spectrometry (UHPLC-MS) combined with univariate and 
multivariate analysis, allowing the metabolic response to stroke in obese mice to be 
identified. 
 
RESULTS 
Stroke alters lipid metabolism in obese mice 
Both control ob/- and obese ob/ob mice lost a significant amount of body weight at 
24 h after stroke, but there was no difference in the absolute weight loss between 
groups (Fig. 1A). However, when expressed as a percentage of pre-surgery weight, 
ob/ob mice lost significantly less weight. In both genotypes, no significant correlation 
was found between ischaemic damage and either absolute or percentage weight 
loss. Stroke resulted in significantly greater (108%) ischaemic damage in obese 
ob/ob compared to ob/- mice. 
Blood glucose levels were significantly increased in obese ob/ob compared to control 
ob/- mice prior to surgery, and at 24 h post-stroke. Blood glucose concentrations 
were not affected by stroke in either control ob/- or obese ob/ob mice as no 
significant difference was observed between blood glucose concentrations at 24 h 
post-stroke when compared to pre-surgery values for obese ob/ob and control ob/-  
separately (Fig. 1B).  
Obesity per se was associated with an increase in plasma FFA, as concentrations 
were significantly greater in naïve ob/ob mice. Stroke then resulted in a further 
increase in plasma FFA in ob/ob mice, with concentrations in obese mice being 
significantly increased relative to both naïve obese mice and control mice post-stroke 
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 (Fig. 1Ci). Plasma glycerol was significantly increased in naïve obese ob/ob mice, 
but there was no effect of stroke in either control or obese mice (Fig. 1Cii).  
In the epididymal adipose tissue of obese ob/ob mice, FFA were elevated in naïve 
mice, though after stroke there was a significant reduction in adipose FFA in obese 
ob/ob mice relative to controls (Fig. 1Di). No effect of genotype or treatment was 
observed in glycerol content in adipose tissue (Fig. 1Dii). 
Liver triglycerides were significantly higher in naïve ob/ob mice compared to control 
ob/- mice, and remained significantly higher after stroke (Fig. 1Ei). However, stroke 
resulted in a significant increase in liver triglycerides in control ob/- mice only. 
Glycerol levels in the liver were significantly higher in naïve obese ob/ob mice. In 
response to stroke there was a significant reduction in liver glycerol in obese ob/ob 
mice but no change in control mice (Fig. Eii). 
 
Obesity differentially affects expression of adipose lipolytic enzymes  
The epididymal adipose tissue expression of the lipolytic enzymes ATGL, HSL, and 
the Ser563 phosphorylated form of HSL, were all similar between naïve control ob/- 
and obese ob/ob mice (Fig. 2). HSL expression in obese ob/ob mice was 
significantly increased 24 h after stroke, but remained unchanged in response to 
stroke in control ob/- mice (Fig. 2A). Conversely, expression of HSL Ser563 was 
significantly increased post-stroke in control ob/- mice, with no effect of stroke seen 
in obese ob/ob mice (Fig. 2B). The expression of ATGL was increased in adipose 
tissue 24 h post-stroke in obese ob/ob compared to naïve obese, but was unaffected 
by stroke in control ob/- mice (Fig. 2C).  
 
Obesity alters the peripheral inflammatory response to stroke in the plasma, 
epididymal fat and liver 
Ischaemic stroke increased expression of some inflammatory mediators as 
measured by cytometric bead array in the plasma, epididymal fat and liver (Fig. 3), 
and this increase was often greater in obese mice. In response to stroke, both obese 
ob/ob and control ob/- mice had significantly increased concentrations of plasma and 
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 liver IL-6, plasma G-CSF and CXCL1 (Figs. 3A and C). However, there were 
significantly greater responses in obese mice in plasma IL-6, G-CSF and CXCL1, 
and liver CXCL1 increased in obese mice only. Furthermore, only obese mice 
showed an increase in inflammatory mediators in the adipose tissue after stroke (Fig. 
3B). Obese mice showed increased expression of inflammatory mediators (IL-6, 
TNFα, ICAM-1) in the epididymal fat after ischaemic stroke, whereas there was no 
significant effect in control mice. Expression of CCL2 was significantly greater in the 
plasma, epididymal fat and liver of obese mice prior to stroke. However, stroke then 
resulted in a significant decrease in CCL2 expression in the plasma and both 
tissues. 
 
Stroke reduced plasma concentrations of the adipokines resistin and 
adiponectin 
The expression of the adipokines resistin and adiponectin were measured in the 
plasma and epididymal adipose tissue by ELISA (Fig. 3). In the epididymal adipose 
tissue in both naïve mice and post-stroke, obese ob/ob mice had significantly lower 
expression of both resistin and adiponectin (Fig. 3B). Similarly, resistin 
concentrations were lower in the plasma of naïve obese mice. Stroke then resulted 
in a significant decrease in plasma concentrations of both resistin and adiponectin 
(Fig. 3A). Post-stroke plasma concentrations of resistin were significantly lower in 
both genotypes, and there was a significant effect of treatment (pre- versus post-
stroke) on adiponectin concentrations. 
 
Untargeted metabolomics identified the obese-specific metabolic response to 
stroke 
Samples were randomly analysed applying a UHPLC-MS platform, appropriate for 
the detection of a wide range of semi-hydrophilic and lipophilic metabolites. To 
calculate the quality of data acquired and to enable quality assurance of the data, a 
single quality control (QC) sample was intermittently analysed every 6th injection 
throughout the run. All metabolite features with a relative standard deviation > 20% 
and where there was greater than 30% missing values were removed from the 
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 dataset prior to data analysis. This process removes poor quality data and 4891 and 
3013 metabolite features remained in positive and negative ion mode, respectively 
post filtering. 
Principal components analysis (PCA) was performed to assess the natural 
variation in the dataset (Fig. 4). The QC samples were tightly clustered compared to 
the biological samples highlighting the reproducibility of the data. The scores plot for 
negative ion mode data (Fig. 4A) showed a separation in principal component 2 
(PC2) related to time; samples from naïve control ob/- and obese ob/ob mice were 
separated from samples from control ob/- and obese ob/ob mice 24 h post-stroke. 
For positive ion mode data (Fig. 4B), separation in PC1 based on control ob/- versus 
obese ob/ob animals was suspected though one sample in the obese 24 h post-
stroke class was different to all other samples in the class, which masked this 
observation.  
Supervised partial least squares-discriminant analysis was performed to 
identify multivariate groups of metabolites that discriminate between ob/- and ob/ob 
mice in naïve animals, and at 24 h post-stroke. Although validated models were 
observed when comparing control and obese animals pre-stroke (naïve), validated 
models were not constructed when comparing control and obese animals 24 h after 
stroke. Therefore further biological analysis of the variable importance in projection 
loadings was not performed.   
Statistical analysis was performed to compare naïve control (ob/-) versus 
naïve obese (ob/ob) mice, and control versus obese animals 24 h post-stroke. False 
discovery rate (FDR) calculations were performed following the Benjamini–Hochberg 
procedure to limit FDR observations. 68 unique metabolites were observed to be 
statistically significant when naïve control mice were compared to naïve obese mice 
(Fig. 5A). Changes in amino acids, fatty acids, oxidised fatty acids, nucleotides, 
glycerophospholipids and lysophospholipids were observed and these results 
indicate metabolic changes related to obesity in the absence of stroke (Table 1). We 
then compared the metabolic profiles of control (ob/-) and obese (ob/ob) mice 24 h 
after stroke. Metabolites that were already found to be significantly altered by obesity 
in naïve animals were excluded from this list, and so the resulting metabolite profile 
is the obese-specific metabolic response to stroke. 83 unique metabolites, not 
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 observed to be statistically significant between naïve control and obese mice, were 
found to be statistically significant when comparing control to obese mice 24 h after 
stroke (Fig. 5B). These metabolites included changes in amino acids, fatty acids, 
oxidised fatty acids, carbohydrates, ceramides and sphingolipids, sulphated 
metabolites, glycerophospholipids and lysophospholipids (Table 2). Metabolic 
pathway enrichment was also performed but showed no statistically significant 
enrichment, primarily because many software do not include lipid metabolism in 
significant detail. 
 
Discussion 
Stroke is known to affect metabolism in humans, with weight loss commonly 
reported in patients where it is associated with poor functional recovery (FOOD Trial 
Collaboration, 2003; Scherbakov and Doehner, 2011). In this context, the metabolic 
reserves found in obesity have been suggested to improve tolerance to post-stroke 
catabolism, therefore improving stroke survival and outcome (Scherbakov et al., 
2011). Weight loss is also found in mice within the first 24 h post-stroke, though 
animals continue to lose weight for a number of days post-stroke (Dirnagl, 2010). 
However, the mediators of this catabolic drive have not been well characterised, 
though are hypothesised to include inflammatory mediators such as IL-6 and TNFα 
(Scherbakov et al., 2011). Previous studies in mice have demonstrated that there is 
an acute inflammatory response in the periphery after stroke, including in 
metabolically active tissues such as the liver and adipose tissue (Denes et al., 
2010b; Offner et al., 2006; Wang et al., 2011a). Therefore, we characterised the 
acute (24 h) metabolic response to stroke and potential inflammatory mediators in 
the context of concurrent obesity (Fig. 6). We show for the first time that the 
metabolic response to stroke is different in obese compared to control mice. This 
observation was primarily related to lipid metabolism, which was also altered naïvely 
in obese animals. The altered metabolic response in obese animals was 
accompanied by increased cytokine expression in the liver and plasma, and an 
obese-specific inflammatory response in the adipose tissue. 
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The initial ischaemic insult in stroke is accompanied by a rapid induction of 
inflammatory cytokines and chemokines in the blood and peripheral organs 
(Chapman et al., 2009; Offner et al., 2006). Here, we found an increased plasma 
response in IL-6, CXCL1 and G-CSF in obese mice after stroke. Increases in plasma 
CXCL-1 have also been observed after stroke in diet-induced obese mice (Maysami 
et al., 2015). In patients, the magnitude of this IL-6 response correlates positively 
with stroke severity (Smith et al., 2004; Smith et al., 2006a). As ob/ob mice have 
worse outcome after experimental stroke, this increased peripheral immune 
response may be a cause or consequence of their increased ischaemic damage 
(Haley and Lawrence, 2016b; Mayanagi et al., 2008; McColl et al., 2010; Terao et 
al., 2008). An exception to the pattern of increased peripheral inflammation in ob/ob 
mice after stroke was the reduction in levels of CCL2 (MCP-1). Plasma CCL2 levels 
in ob/ob mice have been reported to be unaffected by obesity per se, but increased 
after stroke (Terao et al., 2008). However, previous reports in patients suggest that 
plasma CCL2 levels increase with obesity (Kim et al., 2006), potentially explaining 
the high basal levels found here, though the reason for the reduction in CCL2 after 
stoke in obese animals is unclear. Stroke also resulted in an inflammatory response 
in the fat of obese mice characterised by increased IL-6, TNFα and ICAM-1 
expression. A similar pro-inflammatory response has been reported in rats and aged 
mice after MCAO, which is associated with deficits in insulin sensitivity (Shin et al., 
2015; Wang et al., 2011a). Furthermore, surgical removal of visceral fat in aged mice 
prior to MCAO reduced lesion volume (Shin et al., 2015). How this protective effect is 
mediated is unclear, but highlights that the adipose tissue is not just a passive store 
of fat, but is a highly active endocrine organ. Indeed, the adipose tissue in obese 
humans becomes a potent source of inflammatory mediators, including IL-6 and IL-8 
(the mouse homologue of IL-8 is CXCL1) (Fain, 2010). Therefore, the post-stroke 
plasma increases in IL-6 and CXCL1 found in obese mice here could be due to 
increased release from the adipose tissue. 
Adipose tissue is also capable of releasing a growing list of factors termed 
adipokines. Here, we found a decrease in the adipose expression of both resistin 
and adiponectin in obese mice prior to stroke as has been previously reported in 
obesity (Fujinami et al., 2006; Kern et al., 2003). However, we found that stroke 
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 resulted in a decrease in plasma resistin and adiponectin in both control and obese 
mice. As both resistin and adiponectin are exclusively released by adipocytes in 
mice (Banerjee and Lazar, 2003; Scherer et al., 1995), this suggests stroke can alter 
the release of adipokines from adipose tissue. Alterations in plasma adiponectin and 
resistin have both been implicated in stroke risk in patients (Efstathiou et al., 2005; 
Efstathiou et al., 2007), though adipokines more generally could affect stroke 
outcome by modulating the immune system, vasculature, and energy homeostasis 
(Guri and Bassaganya-Riera, 2010; Haley and Lawrence, 2016a; Trayhurn and 
Wood, 2005).  
The accumulation of excess fat in obesity is known to affect lipid metabolism, 
however we found that stroke triggered a further effect on lipid metabolism in obese 
animals that was not seen in controls. This was characterised by an increase in 
plasma FFA, and decrease in epididymal fat FFA at 24 h post-stroke. Plasma FFA 
concentrations are tightly regulated by hormonal regulation to ensure tissues receive 
an appropriate supply of fatty acids for use as an energy source. However, fatty 
acids may also drive pathology, especially when concentrations remain 
inappropriately high (Frayn et al., 1996). The majority of FFAs in the plasma are 
derived from lipolysis of triglycerides within adipocytes (Frayn, 2012), suggesting an 
increase in lipolysis may underlie this increase in obese mice.  
Stroke had differential effects on the expression and phosphorylation of 
lipolytic enzymes in control and obese mice. The activity of lipolytic enzymes in 
adipose tissue determines the rate of hormone-stimulated and basal lipolysis. In 
mice over 95% of triglyceride hydrolysis in adipocytes is due to the enzymes HSL 
and ATGL (Schweiger et al., 2006). In order to quickly respond to fluctuating energy 
requirements, HSL activity is usually mediated by phosphorylation, rather than by a 
change in protein expression (Anthonsen et al., 1998). Through this regulation, HSL 
activity is increased pre-prandially by β-adrenergic stimulation, and decreased post-
prandially by insulin. After experimental stroke, obese mice had increased HSL 
expression but no change in Ser563 phosphorylation. Conversely, in control mice 
stroke had no effect on HSL expression, but increased Ser563 phosphorylation. This 
suggests that HSL was stimulated by hormonal exposure in control mice, but was 
affected by a different mechanism in obese mice. 
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 Rather than being due to hormonal stimulation, increased circulating FFAs 
found in obese mice post-stroke may be due to increased expression of 
inflammatory mediators in the adipose tissue. TNFα has been shown to raise plasma 
FFA levels by acting on the adipose tissue and liver to stimulate basal lipolysis and 
reduce FFA reuptake (Chen et al., 2009). Pro-inflammatory mediators can increase 
basal lipolysis in adipocytes via NF-κB and other inflammatory pathways, with the 
result being an increase in the rate of basal lipolysis independently of HSL 
phosphorylation (Doerrler et al., 1994; Grisouard et al., 2012; Langin and Arner, 
2006). Furthermore, stimulation of lipolysis by the pro-inflammatory endotoxin 
lipopolysaccharide in vivo involves up-regulation of HSL expression without an 
increase in its phosphorylation (Osto et al., 2011). The increase in ATGL expression 
seen in obese mice also suggests an increase in basal lipolysis, since it is an 
important mediator of basal lipolysis in rodents (Langin et al., 2005; Zimmermann et 
al., 2004). Therefore, stroke may trigger an inflammatory response in the adipose 
tissue of obese mice that results in an increase in basal lipolysis, and thus in 
increased plasma FFA concentrations. This may be accompanied by a reduction in 
the clearance of FFAs from the plasma, which has previously been reported in obese 
patients (McQuaid et al., 2011). 
As control ob/- and obese ob/ob mice appeared to show different metabolic 
responses to stroke, particularly in lipid metabolism, we decided to study metabolism 
at the whole organism level by applying non-targeted UHPLC-MS metabolomics. In 
this analysis, obesity per se in the absence of stroke affected several classes of 
metabolites in the plasma of ob/ob mice. These changes were not dependent on 
changes in diet composition as ob/ob mice become obese due to hyperphagia. In 
comparison, metabolomic studies using mice that are obese due to a high-fat diet 
have the caveat of not being able to differentiate effects occurring as a consequence 
of diet, from those occurring as a consequence of obesity (Duggan and Hittel, 2011). 
However, a potential caveat of using the obese ob/ob mouse in the current study is 
their lack of the adipokine leptin, which is known to modulate energy balance and the 
immune system (Trayhurn and Wood, 2005; Zhang et al., 1994). 
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A large number of the metabolites detected as being significantly affected by 
obesity in mice here were lipid related, with lipid species overall being increased in 
obese ob/ob mice, as expected. The largest proportion of these lipids was 
membrane-associated, including glycerophospholipids, lysophospholipids and 
sphingolipids. Lipidomics in humans has demonstrated that obesity generally 
increases the abundance of lipid species, and certain species have been found to 
correlate with body mass index (BMI) including acyl glycerides, 
phosphatidylethanolamines, phosphatidylcholines, and lysophospholipids species 
(Graessler et al., 2009; Oberbach et al., 2011; Wallace et al., 2014). Furthermore, 
several of the lysophospholipids species that increased in obese animals in the 
present study (specifically lysophosphatidylcholines [LysoPCs] 18:0, 18:1 and, 18:2) 
have been correlated with measures of insulin resistance and inflammation in 
patients (Wallace et al., 2014). Mice that develop obesity due to being fed a high-fat 
diet also showed increases in fatty acids, phosphatidylcholines and lysophospholipid 
species (Kim et al., 2011; Sampey et al., 2012). Two specific metabolite or 
metabolite classes which require further investigation are, sphinganine-1-phosphate 
(4 fold higher in naïve ob/ob mice) metabolites, and the metabolite class of 
plasmalogens. The sphinganine-1-phosphate related metabolite sphingosine-1-
phosphate has been implicated in poor outcome for ischemic stroke (Ichijo et al., 
2015; Maceyka et al., 2013; Moon et al., 2015), and therefore sphingolipid 
metabolism before and after stroke is worthy of investigation. Plasmalogens are 
identifiable by their ether linkage at the sn-1 position, and can make up 20% of all 
glycerophosphocholines in the brain (Farooqui and Horrocks, 2001). Plasmalogens 
have numerous important roles in the central nervous system, including protecting 
against reactive oxygen species damage, thus seeing specific metabolites both 
increased and decreased could be relevant for subsequent stroke outcome. 
Beyond effects on lipid metabolism, changes in other metabolites in ob/ob 
mice were suggestive of health complications usually associated with obesity. Obese 
mice had increases in the amino acids leucine and phenylalanine. In patients, these 
were found to predict future diabetes and correlate positively with BMI (Gralka et al., 
2015; Ho et al., 2016; Shah et al., 2012; Wang et al., 2011b). Obese ob/ob mice also 
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 had reduced plasma arginine, being the most greatly reduced (7 fold) metabolite 
species detected. Similar findings of reduced plasma arginine have been made in 
genetically obese Zucker rats (Serkova et al., 2006). Reductions in plasma arginine 
have been implicated in the development of cardiovascular disease (Shah et al., 
2012; Tang and Wang, 2009), potentially because arginine deficiency can result in 
endothelial dysfunction and decreased nitric oxide availability (Morris, 2012). 
Arginine and associated metabolic products have also been demonstrated to be 
acutely elevated post stroke, so the potential impact of reduced arginine found in 
obese subjects on subsequent stroke outcome requires further study (Molnar et al., 
2014). Furthermore, in obese mice a reduction in a carbohydrate deoxy-glucose 
species was observed, which may correspond to 1,5-anhydroglucitol, a marker of 
prolonged hyperglycaemia and predictor of future diabetes (Dungan et al., 2006). 
Overall, the metabolite profile of ob/ob mice shows biomarkers not only of obesity, 
but also aspects of the metabolic syndrome, including insulin resistance, 
dyslipidaemia and cardiovascular disease. This suggests the obese ob/ob mice 
possess a spectrum of risk factors for stroke similar to those seen in obese patients. 
Metabolomic analysis of metabolites in the plasma at 24 h post-stroke was 
performed in both obese ob/ob and control mice. A comparison of these two profiles 
found 83 unique metabolites to be significantly affected by obesity after stroke. As 
this list excluded metabolites detected as being affected by obesity in the absence of 
stroke, this list entails the obese-specific metabolic response to stroke. A large 
number of these species were lipid-related, including several classes of membrane 
lipids. Further changes in glycerophospholipids and lysophospholipids were found in 
addition to those altered by obese mice in the absence of stroke. LysoPC(20:4) was 
increased in obese mice relative to control mice after stroke, and is a reported 
biomarker of ischaemic stroke in patients (Jové et al., 2015; Zhu et al., 2015). Stroke 
also affected long chain sphingomyelin (SM) sphingolipids in obese animals. Two 
species increased in obese mice after stroke, SM(d18:1/18:0) and SM(d18:1/18:1), 
were found to be specific markers of acute traumatic and ischaemic brain injury in 
mice (Sheth et al., 2015). Sphingomyelin lipids also correlated positively with plasma 
IL-8 and TNFα in obese subjects (Wallace et al., 2014), and are implicated in the 
development of cardiovascular disease due to their promotion of pro-inflammatory 
signalling pathways (Nixon, 2009; Sun et al., 2016). Therefore, the upregulation of 
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 sphingomyelins in response to stroke was specific to obese mice, and may be a 
marker of post-stroke inflammation or greater damage in obese mice. Alternatively, 
sphingolipid species may be worsening outcome by activating pro-inflammatory 
signalling pathways (Sun et al., 2016). The increase in oxidised forms of fatty acids 
similar to those found abundantly in obese ob/ob adipose tissue (long chain fatty 
acids, C14 to C18) suggests that fatty acids liberated by lipolysis in obese mice after 
stroke are undergoing incomplete β-oxidation to be used as an energy source. 
The differences in the metabolic response to stroke between obese and 
control animals were not restricted to lipid species, with several classes of non-lipid 
metabolites also significantly affected. Corticosterone was significantly higher in 
obese animals after stroke, suggestive of increased HPA axis activation. Activation 
of the HPA axis results in the release of catecholamines and glucocorticoids that can 
directly stimulate lipolysis, and thus affect plasma lipid concentrations. Amino acids 
were also affected, with obese animals showing reductions in tyrosine and 
methionine, and an increase in taurine. Similar changes in plasma amino acids have 
been reported as biomarkers for ischaemic stroke in both patients and rodents, 
though the directions of these changes vary (Gao et al., 2013; Kimberly et al., 2013; 
Liu et al., 2015; Zhu et al., 2015). As the extent of these changes can correlate with 
the severity of ischaemic damage (Kimberly et al., 2013), the difference between 
obese and control animals found here could be due to increased ischaemic damage 
in obese mice. 
Weight loss for several days after experimental stroke is common in rodents, 
and often correlates with stroke severity (Dirnagl, 2010). In the current study, 
absolute weight loss was similar between obese and control mice, though obese 
mice lost less weight as a percentage of baseline weight. There was also no 
correlation between either measure of weight loss and ischaemic damage. However, 
it unclear from what compartment this weight is being lost at this acute time point. 
For example, weight may be lost not only from adipose tissue, but potentially from 
glycogen stores, muscle or other lean stores. Therefore, weight loss at this acute 
time point may not reflect long-term changes in metabolism. In order to assess the 
acute metabolic response to stroke, we selected an acute time point that is less likely 
to be affected by other complications of stroke such as inactivity and motor deficits. 
However, future work is required to establish whether acute changes in metabolism 
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 translate into longer-term changes in metabolism and outcome, but data here 
suggest that weight changes in obese mice are likely to be altered.  
In the present study, obesity affected the metabolic response to stroke, 
characterised by an increase in plasma FFAs, likely due to an increase in basal 
lipolysis. Metabolomics revealed that the obese-specific response to stroke featured 
changes in various lipid species, including acyl glycerides, sphingolipids, 
glycerophospholipids, lysophospholipids and fatty acids derivatives. This altered 
metabolic response to stroke may be driven by or may drive a post-stroke 
inflammatory response in the adipose tissue of obese mice that was not seen in 
control mice. The adipose tissue has previously undergone little investigation in the 
response to stroke, though may affect outcome due its ability to release adipokines 
and pro-inflammatory cytokines. These differences in the metabolic and 
inflammatory responses to stroke in obese mice highlights the importance of 
considering comorbidities in preclinical studies, especially when considering the 
usefulness of biomarkers of stroke. It will also be important to consider how obesity 
affects the loss of muscle mass after stroke, as this will be an important determinant 
of functional recovery, though pro-inflammatory cytokines are known to promote 
catabolism that can lead to sarcopenia (Kotler, 2000). Overall, whether these results 
support the hypothesis that obesity protects against post-stroke weight loss will 
depend on whether these acute changes in lipolysis, inflammation and metabolism 
translate into longer-term effects on recovery or outcome.  
 
MATERIALS AND METHODS 
 
Mice 
Experiments were performed on 16 to 19 week-old male obese ob/ob 
(C57BL/6OlaHsd-Lepob, n = 26) or male heterozygote ob/- control mice (n = 26; 
Harlan-Olac, UK). Body weight at the time of surgery was 32.5 ± 5.7g for control 
(ob/-) and 54.1 ± 6.0g for obese (ob/ob). All mice were housed in standard conditions 
(temperature of 20 ± 2°C; humidity, 55% ± 5%; 12-hour light/12-hour dark cycle with 
lights on at 08:00 hours) and were given ad libitum access to a standard laboratory 
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 diet (RM1, Special Diet Services, UK) and water. All experimental procedures using 
animals were conducted in accordance with the United Kingdom Animals (Scientific 
Procedures) Act, 1986 and approved by the Home Office and the local Animal 
Ethical Review Group, University of Manchester.  
 
Focal cerebral ischaemia 
Focal cerebral ischaemia was induced in control (ob/-) and obese (ob/ob) mice by 
transient (20 min) middle cerebral artery occlusion (MCAO). We have previously 
published that this approach and duration of occlusion leads to worse outcome in 
ob/ob mice, and this was confirmed in a subset of animals in this study (n = 6 per 
group) (Haley and Lawrence, 2016b). Briefly, under isoflurane anaesthesia, the 
carotid arteries were exposed and a silicone coated filament (coating 210 μm in 
diameter and >=5 mm length, Doccol, USA) was introduced into the external carotid 
artery and advanced along the internal carotid artery until occluding the origin of the 
MCA. Successful MCAO was confirmed by a reduction in cerebral blood flow of at 
least 80% as measured using laser-Doppler (Moor Instruments, UK). After 20 min, 
the filament was withdrawn to establish reperfusion and the wound sutured. During 
surgery, core body temperature was monitored using a rectal probe and maintained 
at 37°, using a homeothermic blanket (Harvard Apparatus, Kent, UK). Animals were 
allowed to recover and at 24 h later they were weighed and re-anesthetised. Cardiac 
blood was collected (with sodium citrate to prevent clotting), spun at 1400 g for 10 
min at 4°C and aliquots of plasma were immediately frozen. Samples of liver and 
epididymal fat pads were also taken for homogenisation in buffer (50 mM Tris-HCL, 
150 mM NaCl, 5 mM CaCl2, 0.02% NaN3, 1% Triton X-100). Naïve animals (n = 10 
per genotype) were treated identically, but underwent no experimental ischaemia. All 
animals were randomly assigned to a treatment group (cerebral ischaemia versus 
naïve). In each of the control ob/- and obese ob/ob stroke groups 16 animals 
underwent surgery, with 2 animals excluded from each group due to subarachnoid 
haemorrhage or death based on pre-established criteria (final n = 14 per genotype). 
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Quantification of cytokines 
Concentrations of cytokines were measured in tissue homogenates or plasma 
samples by cytometric bead array (CBA) as defined by the manufacturer’s 
instructions, with Flex Sets used for IL-6, tumor necrosis factor α (TNFα), CCL2, 
CXCL1 and granulocyte-colony stimulating factor (G-CSF; BD-Biosciences). 
Intracellular adhesion molecule (ICAM-1), adiponectin and resistin were measured in 
epididymal fat homogenates or plasma samples by ELISA according to the 
manufacturer’s instructions (DuoSet, R&D Systems). 
Glucose, free fatty acid, glycerol and triglyceride measurement 
Blood glucose was measured in tail vein blood samples taken immediately prior to 
experimental ischaemia or at time of sacrifice using a hand-held glucose monitor 
(Accu-Chek Aviva, Roche, UK). FFAs and glycerol were quantified in cardiac plasma 
samples and epididymal adipose tissue homogenates, and triglycerides and glycerol 
in liver homogenates, as per manufacturer’s instructions using commercially 
available kits (Zen Bio, USA). 
 
Adipose tissue HSL and ATGL assays 
Expression of hormone sensitive lipase (HSL), its serine-563 phosphorylated form 
(HSL Ser563), and adipose triglyceride lipase (ATGL) were measured in epididymal 
fat pad homogenates by Western blot. Antibodies for immunoblotting were as 
follows: anti-HSL (1:2000, Cell Signalling Technology, USA), anti-HSL Ser563 
(1:500, Cell Signalling Technology), anti-ATGL (1:2000, Cell Signalling Technology), 
and anti-β-actin (1:5000, Sigma). Epididymal adipose tissue homogenates (25 µg 
total protein per well) were separated by SDS page, and proteins transferred to a 
polyvinylidene fluoride membrane. Membranes were then blocked [5% milk and 
0.1% TWEEN-20 in PBS (PBS-T)], and incubated at 4°C overnight in primary 
antibodies diluted in 1% BSA in PBS-T. After being incubated with HRP-conjugated 
secondary antibodies (1:500, Wako Chemicals) in 5% milk in PBS-T, blots were 
developed using an Enhanced Chemiluminescent Detection Kit (GE Healthcare). 
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 Digital images of protein bands were acquired (ImageQuant 350, GE Healthcare, 
UK) and semi-quantitative analysis of protein content performed by densitometry 
using ImageQuant TL software (GE Healthcare, UK), with values normalised to β-
actin as a loading control. 
 
Non-targeted metabolomics 
Mouse plasma was taken from control ob/- and obese ob/ob mice without previous 
treatment (naïve, n = 5-6/group) and at 24 h post-stroke (n = 6-8/group), and 
prepared as previously described (Dunn et al., 2011b). Plasma was thawed on ice 
and deproteinised by addition of 300 μL of methanol to 100 μL of plasma followed by 
vortex mixing (15 sec) and centrifugation (13,365 g for 15 min). The supernatants 
(300 μL) were transferred to 2.0 mL centrifuge tubes and vacuum dried. Prior to 
analysis the dried extracts was reconstituted in 100 μL of 50/50 water/methanol. 
Additionally, pooled quality control (QC) samples were prepared by pooling 75 μL 
aliquots of each biological sample, subsequently 100 μL aliquots were deproteinised, 
dried and reconstituted as described above. 
Samples were analysed twice (in positive ion and negative ion modes) applying an 
Accela UHPLC system interfaced to an electrospray LTQ-Orbitrap Velos hybrid 
mass spectrometer (ThermoFisher Scientific, Hemel Hempstead, UK). 
Chromatographic separations were performed on a Hypersil GOLD column (100 x 
2.1 mm, 1.9 μm; Thermo Fisher Scientific, Runcorn, UK) operating at a column 
temperature of 50°C. A binary gradient elution was applied at a flow rate of 400 
μL.min-1 with two solvents; Solvent A = 0.1% formic acid in water (vol/vol) and 
solvent B = 0.1% formic acid in methanol (vol/vol)). Solvent A was held at 100% for 
0.5 min followed by an increase to 100% solvent B over 15.5 min, which was then 
held at 100% solvent B for a further 5 min. A step change to 100% solvent A was 
performed at 20.5 min and then held at 100% solvent A to equilibrate for 1.5 min. All 
column eluent was transferred to the mass spectrometer and full-scan profiling data 
were acquired in the m/z range 100-1000 in the Orbitrap mass analyser (mass 
resolution 30,000; Full Width Half Maximum at m/z = 400). The source and ion 
transfer parameters applied were as follows; source heater = 200°C, sheath gas = 
50 (arbitrary units), aux gas = 15 (arbitrary units), capillary temperature = 300°C, 
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 ISpray voltage = 4kV (positive-ion mode) and 3kV (negative-ion mode), s lens = 65% 
and AGC = 5 x 105.  
Raw instrument data were converted to netCDF file format with FileConverter 
software available in XCalibur (ThermoFisher Scientific, Bremen, Germany). 
Deconvolution was performed using the freely available XCMS software as 
described previously (Dunn et al., 2011b; Smith et al., 2006b). Data were exported 
from XCMS as a .csv file for further data analysis. The quality of data was assessed 
applying quality control (QC) data as previously described (Smith et al., 2006b), with 
all metabolite features with a RSD>20% or with greater than 30% missing values for 
QC samples being removed from the dataset prior to data analysis. Metabolite 
annotation was performed applying the PUTMEDID_LCMS workflow as previously 
described (Brown et al., 2011). All metabolite annotations are reported at level 2 
according to MSI reporting standards (Sumner et al., 2007). The processed data was 
analysed in R with the univariate t-test applying the Benjamini–Hochberg procedure 
for false discovery rate calculation (q<0.05) after normalisation to total peak area. 
The fold change was calculated applying the median response per class with 95% 
confidence limits. The processed data were also analysed applying unsupervised 
Principal Components Analysis (PCA) and pairwise comparisons of classes applying 
supervised PLS-DA; both of these analyses were performed in the open access 
software MetaboAnalyst (Xia et al., 2012). Metabolites were manually clustered into 
classes defining similar chemical structure or metabolic pathway to identify 
biologically relevant and robust metabolic changes. 
 
Statistical analyses 
All ex vivo analyses were performed blinded to treatment (naïve or MCAO) and 
genotype (control or obese). Sample sizes were determined by power calculation (α 
= 0.05, β = 0.2) of our previous data. Statistical analyses for all non-metabolomics 
data were performed using GraphPad software (GraphPad Software Inc., La Jolla, 
CA, USA). Data was tested for equal variance using the Brown–Forsythe and 
Bartlett's tests, and appropriate transformations applied if necessary. Two-way 
ANOVA was used for comparisons by genotype and by treatment followed by a 
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 Šídák correction for multiple comparisons, and a t-test was used for two groups. 
Correlations between body weight loss and ischaemic damage were assessed by 
Pearson correlation coefficient. All data (apart from metabolomics) are represented 
as mean ± standard error of the mean (s.e.m). P < 0.05 was considered significant.  
 
Acknowledgements 
We would like to thank the Biological Services Facility at the University of 
Manchester for expert animal husbandry husbandry and Paul Begley from the 
Centre for Advanced Discovery and Experimental Therapeutics (CADET), for 
technical support. 
 
Competing interests 
No contributing authors have any competing financial interests in relation to the work 
described. 
 
Author Contributions 
The conception and design of the study was performed by CBL and MJH.  MJH 
performed all experimental in vivo work and data analysis. WBD, GM and KAH 
performed the untargeted metabolomics study. MJH, GJC, WBD and CBL were 
involved in the interpretation of data, and drafting of the manuscript. 
 
Funding 
This work was supported by the Medical Research Council (G1000399-1/1), 
Wellcome Trust (WT087512MA) and the Kohn Foundation.   
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 References 
Anthonsen, M., Rönnstrand, L., Wernstedt, C., Degerman, E. and Holm, C. 
(1998). Identification of Novel Phosphorylation Sites in Hormone-sensitive 
Lipase That Are Phosphorylated in Response to Isoproterenol and Govern 
Activation Properties in Vitro. J. Biol. Chem. 273, 215–221. 
Banerjee, R. R. and Lazar, M. a (2003). Resistin: molecular history and prognosis. 
J. Mol. Med. (Berl). 81, 218–26. 
Brown, M., Wedge, D. C., Goodacre, R., Kell, D. B., Baker, P. N., Kenny, L. C., 
Mamas, M. a, Neyses, L. and Dunn, W. B. (2011). Automated workflows for 
accurate mass-based putative metabolite identification in LC/MS-derived 
metabolomic datasets. Bioinformatics 27, 1108–12. 
Chapman, K. Z., Dale, V. Q., Dénes, Á., Bennett, G., Rothwell, N. J., Allan, S. M. 
and McColl, B. W. (2009). A rapid and transient peripheral inflammatory 
response precedes brain inflammation after experimental stroke. J. Cereb. 
Blood Flow Metab. 29, 1764–1768. 
Chen, X., Xun, K., Chen, L. and Wang, Y. (2009). TNF-alpha, a potent lipid 
metabolism regulator. Cell Biochem. Funct. 27, 407–16. 
Denes, A., Thornton, P., Rothwell, N. J. and Allan, S. M. (2010a). Inflammation 
and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. 
Brain Behav. Immun. 24, 708–723. 
Denes, A., McColl, B. W., Leow-Dyke, S. F., Chapman, K. Z., Humphreys, N. E., 
Grencis, R. K., Allan, S. M. and Rothwell, N. J. (2010b). Experimental stroke-
induced changes in the bone marrow reveal complex regulation of leukocyte 
responses. J. Cereb. Blood Flow Metab. 31, 1036–1050. 
Desgeorges, M. M., Devillard, X., Toutain, J., Divoux, D., Castells, J., 
Bernaudin, M., Touzani, O. and Freyssenet, D. G. (2015). Molecular 
mechanisms of skeletal muscle atrophy in a mouse model of cerebral ischemia. 
Stroke. 46, 1673–1680. 
Dirnagl, U. (2010). Complexities, Confounders, and Challenges in Experimental 
Stroke Research: A Checklist for Researchers and Reviewers. In Rodent 
Models of Stroke (ed. Dirnagl, U.), pp. 263–277. Totowa, NJ: Humana Press. 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Doehner, W., Schenkel, J., Anker, S. D., Springer, J. and Audebert, H. J. (2013). 
Overweight and obesity are associated with improved survival, functional 
outcome, and stroke recurrence after acute stroke or transient ischaemic attack: 
observations from the TEMPiS trial. Eur. Heart J. 34, 268–77. 
Doerrler, W., Feingold, K. R. and Grunfeld, C. (1994). Cytokines induce catabolic 
effects in cultured adipocytes by multiple mechanisms. Cytokine 6, 478–84. 
Duggan, G. and Hittel, D. (2011). Differentiating short- and long-term effects of diet 
in the obese mouse using 1H-nuclear magnetic resonance metabolomics. 
Diabetes. Obes. Metab. 859–862. 
Dungan, K. M., Buse, J. B., Largay, J., Kelly, M. M., Button, E. a, Kato, S. and 
Wittlin, S. (2006). 1,5-Anhydroglucitol and Postprandial Hyperglycemia As 
Measured By Continuous Glucose Monitoring System in Moderately Controlled 
Patients With Diabetes. Diabetes Care 29, 1214–9. 
Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R. and Griffin, J. L. 
(2011a). Systems level studies of mammalian metabolomes: the roles of mass 
spectrometry and nuclear magnetic resonance spectroscopy. Chem. Soc. Rev. 
40, 387–426. 
Dunn, W. B., Broadhurst, D., Begley, P., Zelena, E., Francis-McIntyre, S., 
Anderson, N., Brown, M., Knowles, J. D., Halsall, A., Haselden, J. N., et al. 
(2011b). Procedures for large-scale metabolic profiling of serum and plasma 
using gas chromatography and liquid chromatography coupled to mass 
spectrometry. Nat. Protoc. 6, 1060–83. 
Efstathiou, S., Tsioulos, D. I., Tsiakou, A. G., Gratsias, Y. E., Pefanis, A. V and 
Mountokalakis, T. D. (2005). Plasma adiponectin levels and five-year survival 
after first-ever ischemic stroke. Stroke 36, 1915–1919. 
Efstathiou, S., Tsiakou, A. G., Tsioulos, D. I., Panagiotou, T. N., Pefanis, A. V, 
Achimastos, A. D. and Mountokalakis, T. D. (2007). Prognostic significance of 
plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin. 
Chim. Acta. 378, 78–85. 
Fain, J. N. (2010). Release of inflammatory mediators by human adipose tissue is 
enhanced in obesity and primarily by the nonfat cells: a review. Mediat. Inflamm 
2010, 513948. 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Farooqui,  a a and Horrocks, L. a (2001). Plasmalogens: workhorse lipids of 
membranes in normal and injured neurons and glia. Neuroscientist 7, 232–245. 
Fassbender, K., Schmidt, R., Mossner, R., Daffertshofer, M. and Hennerici, M. 
(1994). Pattern of activation of the hypothalamic-pituitary-adrenal axis in acute 
stroke. Relation to acute confusional state, extent of brain damage, and clinical 
outcome. Stroke 25, 1105–1108. 
FOOD Trial Collaboration (2003). Poor nutritional status on admission predicts 
poor outcomes after stroke: observational data from the FOOD trial. Stroke 34, 
1450–6. 
Frayn, K. N. (2012). Organs and tissues. In Metabolic Regulation: A Human 
Perspective, pp. 92–143. Wiley-Blackwell. 
Frayn, K., Williams, C. and Arner, P. (1996). Are increased plasma non-esterified 
fatty acid concentrations a risk marker for coronary heart disease and other 
chronic diseases? Clin. Sci. 90, 243–253. 
Fujinami, A., Ohta, K., Matsui, H., Kitada, N., Kituara, Y., Kawahara, Y., 
Obayashi, H., Kuno, S., Nakamura, N. and Ohta, M. (2006). Resistin 
Concentrations in Murine Adipose Tissue and Serum Measured by a New 
Enzyme Immunoassay. Obesity 14, 199–205. 
Gao, J., Yang, H., Chen, J., Fang, J., Chen, C., Liang, R., Yang, G., Wu, H., Wu, 
C. and Li, S. (2013). Analysis of serum metabolites for the discovery of amino 
acid biomarkers and the effect of galangin on cerebral ischemia. Mol. Biosyst. 9, 
2311–21. 
Graessler, J., Schwudke, D., Schwarz, P. E. H., Herzog, R., Shevchenko, A. and 
Bornstein, S. R. (2009). Top-down lipidomics reveals ether lipid deficiency in 
blood plasma of hypertensive patients. PLoS One 4, e6261. 
Gralka, E., Luchinat, C., Tenori, L., Ernst, B., Thurnheer, M. and Schultes, B. 
(2015). Metabolomic fingerprint of severe obesity is dynamically affected by 
bariatric surgery in a procedure-dependent manner. Am. J. Clin. Nutr. 102, 
1313–1322. 
Grisouard, J., Bouillet, E., Timper, K., Radimerski, T., Dembinski, K., Frey, D. 
M., Peterli, R., Zulewski, H., Keller, U., Müller, B., et al. (2012). Both 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 inflammatory and classical lipolytic pathways are involved in lipopolysaccharide-
induced lipolysis in human adipocytes. Innate Immun. 18, 25–34. 
Guri, A. J. and Bassaganya-Riera, J. (2010). Systemic Effects of White Adipose 
Tissue Dysregulation and Obesity-Related Inflammation. Obesity. 
Haley, M. J. and Lawrence, C. B. (2016a). Obesity and stroke: Can we translate 
from rodents to patients? J. Cereb. Blood Flow Metab. [Epub ahead of print]. 
Haley, M. J. and Lawrence, C. B. (2016b). The blood-brain barrier after stroke: 
Structural studies and the role of transcytotic vesicles. J. Cereb. Blood Flow 
Metab. 0271678X16629976. 
Ho, J. E., Larson, M. G., Ghorbani, A., Cheng, S., Chen, M. H., Keyes, M., Rhee, 
E. P., Clish, C. B., Vasan, R. S., Gerszten, R. E., et al. (2016). Metabolomic 
profiles of body mass index in the framingham heart study reveal distinct 
cardiometabolic phenotypes. PLoS One 11, 1–16. 
Ichijo, M., Ishibashi, S., Li, F., Yui, D., Miki, K., Mizusawa, H. and Yokota, T. 
(2015). Sphingosine-1-phosphate receptor-1 selective agonist enhances 
collateral growth and protects against subsequent stroke. PLoS One 10, 1–19. 
Jové, M., Mauri-Capdevila, G., Suárez, I., Cambray, S., Sanahuja, J., Quílez, A., 
Farré, J., Benabdelhak, I., Pamplona, R., Portero-Otín, M., et al. (2015). 
Metabolomics predicts stroke recurrence after transient ischemic attack. 
Neurology 84, 36–45. 
Kern, P. A., Gregorio, G. B. Di, Lu, T., Rassouli, N. and Ranganathan, G. (2003). 
Adiponectin Expression From Human Adipose Tissue. Relation to Obesity, 
Insulin Resistance, and Tumor Necrosis Factor Expression. Diabetes 52, 1779–
1785. 
Kim, C. S., Park, H. S., Kawada, T., Kim, J. H., Lim, D., Hubbard, N. E., Kwon, B. 
S., Erickson, K. L. and Yu, R. (2006). Circulating levels of MCP-1 and IL-8 are 
elevated in human obese subjects and associated with obesity-related 
parameters. Int. J. Obes. 30, 1347–1355. 
Kim, H.-J., Kim, J. H., Noh, S., Hur, H. J., Sung, M. J., Hwang, J.-T., Park, J. H., 
Yang, H. J., Kim, M.-S., Kwon, D. Y., et al. (2011). Metabolomic analysis of 
livers and serum from high-fat diet induced obese mice. J. Proteome Res. 10, 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 722–31. 
Kimberly, W. T., Wang, Y., Pham, L., Furie, K. L. and Gerszten, R. E. (2013). 
Metabolite profiling identifies a branched chain amino acid signature in acute 
cardioembolic stroke. Stroke. 44, 1389–95. 
Kotler, D. (2000). Cachexia. Ann. Intern. Med. 133, 622–634. 
Langin, D. and Arner, P. (2006). Importance of TNFalpha and neutral lipases in 
human adipose tissue lipolysis. Trends Endocrinol. Metab. 17, 314–20. 
Langin, D., Dicker, A. and Tavernier, G. (2005). Adipocyte lipases and defect of 
lipolysis in human obesity. Diabetes 54,. 
Lim, H. and Choue, R. (2013). Impact of nutritional status and dietary quality on 
stroke: do we need specific recommendations? Eur. J. Clin. Nutr. 67, 548–54. 
Liu, M., Zhou, K., Li, H., Dong, X., Tan, G., Chai, Y., Wang, W. and Bi, X. (2015). 
Potential of serum metabolites for diagnosing post-stroke cognitive impairment. 
Mol. BioSyst. 11, 3287–3296. 
Maceyka, M., Harikumar, K. B., Milstien, S. and Spiegel, S. (2013). Sphingosine-
1-phosphate signaling and its role in disease. 22, 50–60. 
Mayanagi, K., Katakam, P. V, Gaspar, T., Domoki, F. and Busija, D. W. C.-
2632795 (2008). Acute treatment with rosuvastatin protects insulin resistant 
(C57BL/6J ob/ob) mice against transient cerebral ischemia. J Cereb Blood Flow 
Metab 28, 1927–1935. 
Maysami, S., Haley, M. J., Gorenkova, N., Krishnan, S., McColl, B. W. and 
Lawrence, C. B. (2015). Prolonged diet-induced obesity in mice modifies the 
inflammatory response and leads to worse outcome after stroke. J. 
Neuroinflammation 12, 140. 
McColl, B. W., Rose, N., Robson, F. H., Rothwell, N. J. and Lawrence, C. B. 
(2010). Increased brain microvascular MMP-9 and incidence of haemorrhagic 
transformation in obese mice after experimental stroke. J. Cereb. Blood Flow 
Metab. 30, 267–72. 
McQuaid, S., Hodson, L. and Neville, M. (2011). Downregulation of adipose tissue 
fatty acid trafficking in obesity: a driver for ectopic fat deposition? Diabetes 60, 
47–55. 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Mitchell, A. (1997). Clinical implications of poststroke hypothalamo-pituitary adrenal 
axis dysfunction: A critical literature review. J. Stroke Cerebrovasc. Dis. 6, 377–
88. 
Molnar, T., Pusch, G., Papp, V., Feher, G., Szapary, L., Biri, B., Nagy, L., Keki, S. 
and Illes, Z. (2014). The L-arginine pathway in acute ischemic stroke and 
severe carotid stenosis: Temporal profiles and association with biomarkers and 
outcome. J. Stroke Cerebrovasc. Dis. 23, 2206–2214. 
Moon, E., Han, J. E., Jeon, S., Ryu, J. H., Choi, J. W. and Chun, J. (2015). 
Exogenous S1P Exposure Potentiates Ischemic Stroke Damage That Is 
Reduced Possibly by Inhibiting S1P Receptor Signaling. Mediators Inflamm. 
2015, 11–14. 
Morris, S. M. (2012). Arginases and arginine deficiency syndromes. Curr. Opin. Clin. 
Nutr. Metab. Care 15, 64–70. 
Nixon, G. F. (2009). Sphingolipids in inflammation: pathological implications and 
potential therapeutic targets. Br. J. Pharmacol. 158, 982–93. 
Oberbach, A., Bl, M., Wirth, H., Till, H., Kovacs, P., Kullnick, Y., Schlichting, N., 
Tomm, J. M., Rolle-kampczyk, U., Murugaiyan, J., et al. (2011). Combined 
Proteomic and Metabolomic Profiling of Serum Reveals Association of the 
Complement System with Obesity and Identifies Novel Markers of Body Fat 
Mass Changes. 4769–4788. 
Offner, H., Subramanian, S., Parker, S. M., Afentoulis, M. E., Vandenbark, A. a 
and Hurn, P. D. (2006). Experimental stroke induces massive, rapid activation 
of the peripheral immune system. J. Cereb. Blood Flow Metab. 26, 654–665. 
Osto, M., Zini, E., Franchini, M., Wolfrum, C., Guscetti, F., Hafner, M., 
Ackermann, M., Reusch, C. E. and Lutz, T. a (2011). Subacute endotoxemia 
induces adipose inflammation and changes in lipid and lipoprotein metabolism in 
cats. Endocrinology 152, 804–15. 
Patti, G. J., Yanes, O. and Siuzdak, G. (2012). Innovation: Metabolomics: the 
apogee of the omics trilogy. Nat. Rev. Mol. Cell Biol. 13, 263–269. 
Sampey, B. P., Freemerman, A. J., Zhang, J., Kuan, P.-F., Galanko, J. a, 
O’Connell, T. M., Ilkayeva, O. R., Muehlbauer, M. J., Stevens, R. D., 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Newgard, C. B., et al. (2012). Metabolomic profiling reveals mitochondrial-
derived lipid biomarkers that drive obesity-associated inflammation. PLoS One 
7, e38812. 
Scherbakov, N. and Doehner, W. (2011). Sarcopenia in stroke-facts and numbers 
on muscle loss accounting for disability after stroke. J. Cachexia. Sarcopenia 
Muscle 2, 5–8. 
Scherbakov, N., Dirnagl, U. and Doehner, W. (2011). Body weight after stroke: 
lessons from the obesity paradox. Stroke. 42, 3646–50. 
Scherer, P. E., Williams, S., Fogliano, M., Baldini, G. and Lodish, H. F. (1995). A 
novel serum protein similar to C1q, produced exclusively in adipocytes. J. Biol. 
Chem. 270, 26746–26749. 
Schweiger, M., Schreiber, R., Haemmerle, G., Lass, A., Fledelius, C., Jacobsen, 
P., Tornqvist, H., Zechner, R. and Zimmermann, R. (2006). Adipose 
triglyceride lipase and hormone-sensitive lipase are the major enzymes in 
adipose tissue triacylglycerol catabolism. J. Biol. Chem. 281, 40236–41. 
Serkova, N. J., Jackman, M., Brown, J. L., Liu, T., Hirose, R., Roberts, J. P., 
Maher, J. J. and Niemann, C. U. (2006). Metabolic profiling of livers and blood 
from obese Zucker rats. J. Hepatol. 44, 956–62. 
Shah, S. H., Kraus, W. E. and Newgard, C. B. (2012). Metabolomic profiling for the 
identification of novel biomarkers and mechanisms related to common 
cardiovascular diseases: form and function. Circulation 126, 1110–20. 
Sheth, S. A., Iavarone, A. T., Liebeskind, D. S., Won, S. J. and Swanson, R. A. 
(2015). Targeted lipid profiling discovers plasma biomarkers of acute brain 
injury. PLoS One 10, 1–15. 
Shin, J. a., Jeong, S. I., Kim, M.-S., Yoon, J. C., Kim, H.-S. and Park, E.-M. 
(2015). Visceral adipose tissue inflammation is associated with age-related brain 
changes and ischemic brain damage in aged mice. Brain. Behav. Immun. 50, 
221–231. 
Smith, C. J., Emsley, H. C. A., Gavin, C. M., Georgiou, R. F., Vail, A., Barberan, 
E. M., Zoppo, G. J., Hallenbeck, J. M., Rothwell, N. J., Hopkins, S. J., et al. 
(2004). Peak plasma interleukin-6 and other peripheral markers of inflammation 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 in the first week of ischaemic stroke correlate with brain infarct volume, stroke 
severity and long-term outcome. BMC Neurol. 4, 1–8. 
Smith, C. J., Emsley, H. C. A., Vail, A., Georgiou, R. F., Rothwell, N. J., Tyrrell, 
P. J. and Hopkins, S. J. (2006a). Variability of the systemic acute phase 
response after ischemic stroke. J. Neurol. Sci. 251, 77–81. 
Smith, C. a, Want, E. J., O’Maille, G., Abagyan, R. and Siuzdak, G. (2006b). 
XCMS: processing mass spectrometry data for metabolite profiling using 
nonlinear peak alignment, matching, and identification. Anal. Chem. 78, 779–87. 
Springer, J., Schust, S., Peske, K., Tschirner, A., Rex, A., Engel, O., 
Scherbakov, N., Meisel, A., Von Haehling, S., Boschmann, M., et al. (2014). 
Catabolic signaling and muscle wasting after acute ischemic stroke in mice: 
Indication for a stroke-specific sarcopenia. Stroke 45, 3675–3683. 
Strazzullo, P., D’Elia, L., Cairella, G., Garbagnati, F., Cappuccio, F. P. and 
Scalfi, L. (2010). Excess body weight and incidence of stroke: meta-analysis of 
prospective studies with 2 million participants. Stroke. 41, e418-26. 
Sumner, L. W., Amberg, A., Barrett, D., Beale, M. H., Beger, R., Daykin, C. a., 
Fan, T. W.-M., Fiehn, O., Goodacre, R., Griffin, J. L., et al. (2007). Proposed 
minimum reporting standards for chemical analysis. Metabolomics 3, 211–221. 
Sun, N., Keep, R. F., Hua, Y. and Xi, G. (2016). Critical Role of the Sphingolipid 
Pathway in Stroke: a Review of Current Utility and Potential Therapeutic 
Targets. Transl. Stroke Res. 7, 420–438. 
Tang, W. and Wang, Z. (2009). Diminished global arginine bioavailability and 
increased arginine catabolism as metabolic profile of increased cardiovascular 
risk. J Am Coll Cardiol 53, 2061–2067. 
Terao, S., Yilmaz, G., Stokes, K. Y., Ishikawa, M., Kawase, T. and Granger, D. N. 
(2008). Inflammatory and injury responses to ischemic stroke in obese mice. 
Stroke. 39, 943–50. 
Trayhurn, P. and Wood, I. S. (2005). Signalling role of adipose tissue: adipokines 
and inflammation in obesity. Biochem. Soc. Trans. 33, 1078–1081. 
Vemmos, K., Ntaios, G., Spengos, K., Savvari, P., Vemmou, A., Pappa, T., 
Manios, E., Georgiopoulos, G. and Alevizaki, M. (2011). Association between 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. 
Stroke. 42, 30–6. 
Wallace, M., Morris, C., O’Grada, C. M., Ryan, M., Dillon, E. T., Coleman, E., 
Gibney, E. R., Gibney, M. J., Roche, H. M. and Brennan, L. (2014). 
Relationship between the lipidome, inflammatory markers and insulin resistance. 
Mol. Biosyst. 10, 1586–95. 
Wang, Y.-Y., Lin, S.-Y., Chuang, Y.-H., Chen, C.-J., Tung, K.-C. and Sheu, W. H.-
H. (2011a). Adipose proinflammatory cytokine expression through sympathetic 
system is associated with hyperglycemia and insulin resistance in a rat ischemic 
stroke model. Am. J. Physiol. Endocrinol. Metab. 300, E155-63. 
Wang, T. J., Larson, M. G., Vasan, R. S., Cheng, S., Rhee, E. P., McCabe, E., 
Lewis, G. D., Fox, C. S., Jacques, P. F., Fernandez, C., et al. (2011b). 
Metabolite profiles and the risk of developing diabetes. Nat. Med. 17, 448–53. 
Xia, J., Mandal, R., Sinelnikov, I. V, Broadhurst, D. and Wishart, D. S. (2012). 
MetaboAnalyst 2.0--a comprehensive server for metabolomic data analysis. 
Nucleic Acids Res. 40, W127-33. 
Zhang, Y. Y., Proenca, R., Maffei, M., Barone, M., Leopold, L. and Friedman, J. 
M. (1994). Positional cloning of the mouse obese gene and its human 
homologue. Nature 372, 425–432. 
Zhu, Y., Guo, Z., Zhang, L., Zhang, Y., Chen, Y., Nan, J., Zhao, B., Xiao, H., 
Wang, Z. and Wang, Y. (2015). System-wide assembly of pathways and 
modules hierarchically reveal metabolic mechanism of cerebral ischemia. Sci. 
Rep. 5, 1–15. 
Zimmermann, R., Strauss, J. G., Haemmerle, G., Schoiswohl, G., Birner-
Gruenberger, R., Riederer, M., Lass, A., Neuberger, G., Eisenhaber, F., 
Hermetter, A., et al. (2004). Fat mobilization in adipose tissue is promoted by 
adipose triglyceride lipase. Science 306, 1383–6. 
 
 
  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 Tables 
Table 1. Changes in plasma metabolites in naïve obese (ob/ob) compared to control (ob/-) mice. 
Class Metabolites 
Fold 
(Ob/Cntrl) 
95% CI 
Lower 
95% CI 
Upper 
P value 
Acyl glycerides DG(33:1) 1.82 1.52 2.22 0.0066 
  TG(34:2) 0.47 0.35 0.62 0.0252 
Amino acid metabolism Arginine 0.14 0.02 0.26 0.0017 
 
Leucine; Isoleucine; Norleucine 1.43 1.28 1.59 0.0096 
 
Tryptophan 1.79 1.54 2.04 0.0270 
  Phenylalanine 1.43 1.22 1.67 0.0355 
Aromatic metabolite Cresol 1.28 1.14 1.45 0.0426 
Carbohydrate related 6-(alpha-D-Glucosaminyl)-1D-myo-inositol 1.56 1.43 1.72 0.0019 
  Deoxy-glucose; rhamnose;  rhamnulose 0.53 0.40 0.69 0.0159 
Ceramides and sphingolipids GluCer(d18:1/18:0); GalCer(d18:1/18:0) 2.70 1.82 4.35 0.0287 
  Sphinganine 1-phosphate 4.55 2.94 6.67 0.0484 
Fatty acids related Icosatrienoic acid (c20:3); eicosadienoic acid (c20:2) 0.21 0.14 0.29 0.0037 
 
Octadecanoic acid (C18:0) 1.69 1.41 2.04 0.0291 
  Octadecatrienoic acid (C18:3) 0.71 0.60 0.85 0.0467 
Glycerophospholipids PC(O-15:0/O-1:0); PC(O-8:0/O-8:0); PC(O-16:0/0:0) 0.30 0.17 0.43 0.0027 
 
PC(O-16:0/3:0); PC(O-17:0/2:0); PC(O-18:0/1:0) 0.30 0.18 0.42 0.0035 
 
PE(42:9); PA(41:1) 2.27 1.79 2.94 0.0078 
 
PG(32:5) 1.92 1.64 2.27 0.0093 
 
PC(38:2) 2.33 1.79 3.13 0.0103 
 
PG(O-18:0/17:0); PG(O-20:0/15:0); PG(O-16:0/19:0) 2.78 2.38 3.23 0.0122 
 
PS(41:4); PS(39:1) 1.82 1.52 2.22 0.0123 
 
PC(O-16:0/17:0); PE(O-16:0/20:0) 2.78 2.04 3.85 0.0131 
 
PS(40:9); PE(40:10); PS(33:1) 0.32 0.18 0.50 0.0140 
 
PC(40:6); PC(38:3); PC(18:0/dm18:1) 1.92 1.59 2.33 0.0148 
 
PS(39:5); PS(36:2); PC(35:0) 2.33 1.67 3.45 0.0183 
 
PA(33:2) 2.63 1.85 4.17 0.0220 
 
PA(O-20:0/17:2); PA(P-18:0/19:1); PA(P-20:0/17:1) 1.59 1.35 1.85 0.0227 
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PC(40:7); PC(38:4); PC(36:1) 2.04 1.45 3.03 0.0260 
 
PS(41:3); PS(39:0) 1.75 1.41 2.22 0.0268 
 
PS(41:2); PE(42:3); PC(38:3) 2.56 1.69 4.17 0.0270 
 
PC(38:4); PE(P-20:0/22:6); PS(O-18:0/19:1) 1.41 1.16 1.75 0.0426 
 
PS(43:6); PC(38:4)PC(36:1); PC(40:7) 1.61 1.30 2.08 0.0479 
 
PC(36:2) 2.56 1.72 4.00 0.0483 
  PC(22:4/dm18:0); PS(39:3) 2.33 1.67 3.13 0.0493 
Lysophospholipids LysoPC(20:4); LysoPC(18:1) 1.54 1.37 1.75 0.0030 
 
LysoPC(18:2) 0.78 0.72 0.83 0.0037 
 
LysoPA(18:2) 0.35 0.24 0.46 0.0093 
 
LysoPC(dm18:1) 1.75 1.43 2.17 0.0103 
 
LysoPA(20:3); LPA(18:0); LPA(18:0) 0.81 0.75 0.88 0.0148 
 
LysoPS(12:0) 2.27 1.79 2.94 0.0168 
 
LysoPA(15:1) 0.59 0.48 0.72 0.0268 
 
LysoPC(20:1) 0.65 0.56 0.76 0.0269 
 
LysoPE(18:1) 0.49 0.29 0.70 0.0269 
 
LysoPC(18:1) 1.41 1.18 1.72 0.0331 
 
LysoPE(22:4) 1.59 1.35 1.85 0.0358 
 
LysoPC(18:0) 1.35 1.20 1.52 0.0358 
 
LysoPE(18:2); LysoPA(20:3) 0.43 0.26 0.63 0.0401 
  LysoPC(22:1) 0.39 0.13 0.67 0.0432 
Mixed classes PA(34:0) 0.76 0.69 0.84 0.0172 
 
Palmitic amide; hexadecadienol 0.78 0.70 0.88 0.0217 
 
3-Dehydroxycarnitine; aminoheptanoic acid; methylleucine 1.79 1.41 2.27 0.0234 
  Aconitate; Dehydroascorbic acid 3.70 2.22 7.69 0.0314 
Nucleosides and nucleotides UDP-N-acetylmuramate 1.67 1.39 2.04 0.0078 
 
Guanosine diphosphate adenosine 2.27 1.61 3.45 0.0166 
 
3-(ADP)-glycerate; lacty (2) diphospho-(5')guanosine 0.63 0.51 0.78 0.0460 
  L-Alpha-Glycerophospho-D-Myo-Inositol-4,5-Bis-Phosphate; dITP 0.70 0.56 0.86 0.0469 
Other classes Pantothenic acid 2.50 1.89 3.33 0.0270 
 
Nicotinamide adenine dinucleotide phosphate 1.85 1.43 2.44 0.0285 
 
Lipoamide 1.89 1.47 2.44 0.0362 
  3,5-Diiodo-4-hydroxyphenylpyruvate 1.54 1.27 1.85 0.0362 
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 Oxidised fatty acids Oxo-heptadecatrienoic acid (C17:3 oxo); hydroxy-heptadecatrienoic acid 1.89 1.67 2.13 0.0083 
 
2,3,4,5-tetranor-9S,11R,15S-trihydroxy-13E-prostenoic acid 0.38 0.21 0.56 0.0138 
 
Docosanol 1.64 1.37 2.04 0.0169 
 
Oxo-decadienoic acid (C10:2 oxo) 0.33 0.24 0.43 0.0220 
  2,3-Dinor-8-iso prostaglandin F1alpha; hydroperoxy-epoxyoctadecenoic 
acid 
2.08 1.56 2.70 0.0460 
Peptides L-gamma-glutamyl-L-isoleucine; L-gamma-glutamyl-L-leucine 1.89 1.56 2.27 0.0167 
  Glutamyl-phenylalanine 1.89 1.54 2.27 0.0285 
Sugar alcohol Erythronic acid; Threonic acid 0.50 0.41 0.60 0.0093 
 
Fold change is obese (Ob) divided by control (Cntrl). Metabolites are listed from most to least significant in each class. In the fold change column, 
metabolites increased in ob/ob relative to ob/- mice are in red, and metabolites decreased in ob/ob relative to ob/- mice are in blue. P values are 
FDR adjusted. The species listed are the potential identifies of each metabolite. n = 5-6 animals per group. ADP – adenosine diphosphate, Cer – 
ceramide, DG – Diglyceride, dITP – deoxyinosine triphosphate, GalCer – galactosylceramide, GluCer – glucosylceramide, MG – Monoglyceride, PA 
– phosphatidic acid, PC – phosphatidylcholine, PE – phosphatidylethanolamine, PG – phosphatidylglycerol, PS – phosphatidylserine, SM – 
sphingomyelin, TG – triglyceride, UDP – uridine diphosphate.  
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 Table 2. Changes in plasma metabolites in obese (ob/ob) compared to control (ob/-) mice 24 h post-stroke. 
Class Metabolites 
Fold 
(Ob/Cntrl) 
95% CI 
Lower 
95% CI 
Upper 
P value 
Acyl carnitines Propanoylcarnitine 2.38 1.64 3.23 0.0371 
Acyl glycerides DG(34:4) 1.49 1.23 1.85 0.0181 
 
MG(22:2) 2.44 1.85 3.13 0.0396 
 
DG(40:9) 1.45 1.18 1.79 0.0399 
  DG(34:3); DG(32:0) 0.40 0.17 0.71 0.0482 
Amino acid metabolism Methionine S-oxide 0.59 0.45 0.75 0.0135 
 
N-Succinyl-L-glutamate 2.33 1.67 3.23 0.0193 
 
Methionine 0.64 0.47 0.81 0.0238 
 
Tyrosine 0.58 0.46 0.74 0.0292 
 
Taurine 1.96 1.47 2.50 0.0310 
 
N-Acetyl-citrulline 1.61 1.27 2.04 0.0331 
  S-Glutaryldihydrolipoamide 2.22 1.52 2.94 0.0468 
Aromatic metabolite Indole-3-acetate; 3-indoleglycolaldehyde; 5-hydroxyindoleacetaldehyde 3.45 2.33 4.76 0.0312 
Carbohydrates related Sorbitol; galactitol; mannitol 0.60 0.51 0.71 0.0167 
 
N-Acetyl-O-acetylneuraminate 0.56 0.43 0.71 0.0180 
  sn-glycero-3-Phospho-1-inositol; 2-(alpha-D-Galactosyl)-sn-glycerol 3-phosphate 2.27 1.64 3.03 0.0263 
Ceramides and sphingolipids SM(d18:1/18:0); SM(d18:0/18:1) 3.33 2.33 5.56 0.0004 
 
SM(d18:1/20:0) 0.35 0.22 0.48 0.0005 
 
N-(2-hydroxydodecanoyl)-4,8-sphingadienine 1.92 1.43 2.63 0.0161 
 
SM(d18:1/18:1) 2.08 1.43 3.33 0.0221 
 
Cer(d18:2/15:0) 1.89 1.32 3.13 0.0334 
  SM(d18:1/14:0) 1.96 1.32 3.45 0.0337 
Fatty acid related Octadecadienoic acid (C18:2) 0.63 0.56 0.69 0.0001 
 
Decyl hexacosanoate; dodecyl tetracosanoate; eicosanyl hexadecanoate 1.56 1.28 1.89 0.0174 
 
Hexadecadienoic acid (C16:2) 1.85 1.33 2.56 0.0393 
 
Methyl-tetradecanedioic acid; pentadecanedioic acid (C15:0) 0.69 0.53 0.87 0.0445 
 
Eicosanyl oleate 1.89 1.25 3.13 0.0476 
 
Icosatetraenoic acid; eicosatetraenoic acid (C20:4) 1.43 1.19 1.75 0.0478 
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Methyl-eicosadienoic acid; heneicosadienoic acid (C21:2) 1.64 1.22 2.17 0.0480 
  Dodecanamide (C12:1) 0.71 0.58 0.87 0.0493 
Fatty acid-amino acid esters N-hexadecanoylglycine 1.85 1.32 2.78 0.0317 
Glycerophospholipids PA(O-18:0/22:2); PA(O-20:0/20:2); PA(P-18:0/22:1) 0.75 0.71 0.79 0.0001 
 
PE(34:2) 0.26 0.14 0.40 0.0016 
 
PS(P-20:0/22:4); PS(O-18:0/22:2); PS(O-20:0/20:2) 1.79 1.56 2.04 0.0032 
 
PC(20:5/dm18:1); PC(22:6/dm16:0); PS(37:5) 2.17 1.85 2.50 0.0085 
 
PC(33:2); PE(36:1); PA(38:3) 0.69 0.64 0.76 0.0180 
 
PC(34:2); PE(37:2) 2.22 1.64 3.33 0.0186 
 
PS(39:1); PC(22:5/dm18:1); PC(22:6/dm18:0) 0.82 0.74 0.90 0.0188 
 
DG(38:6) 0.50 0.28 0.72 0.0189 
 
PC(36:4); PC(34:1); PA(41:5) 1.82 1.54 2.70 0.0238 
 
PC(38:7); PC(36:4); PC(34:1) 2.08 1.43 2.27 0.0238 
 
PG(O-20:0/18:0); PG(O-18:0/20:0); PG(O-16:0/22:0) 0.40 0.15 0.66 0.0259 
 
PE(14:0/dm16:0) 2.27 1.59 3.23 0.0264 
 
PC(34:1); PA(39:2) 1.72 1.39 2.13 0.0285 
 
PA(O-16:0/18:4); PA(P-16:0/18:3) 2.08 1.45 3.13 0.0297 
 
PS(36:2); PE(38:6); PC(33:3) 0.50 0.35 0.68 0.0304 
 
PC(18:0/dm18:0); PC(20:0/dm16:0); PC(O-16:0/20:1) 1.56 1.27 1.89 0.0309 
 
PS(39:5); PS(37:2); PE(38:0) 1.89 1.32 2.78 0.0313 
 
PI(36:3) 1.79 1.37 2.22 0.0382 
 
PS(O-20:0/19:1); PS(P-18:0/21:0); PS(P-20:0/19:0) 0.56 0.50 0.79 0.0396 
 
PA(24:0); PC(O-18:1/0:0); PC(P-18:0/0:0) 0.64 0.42 0.72 0.0396 
 
PG(O-18:0/19:1); PG(O-20:0/17:1); PG(P-16:0/21:0) 2.50 1.69 3.33 0.0408 
 
PA(O-20:0/22:4) 1.43 1.18 1.72 0.0413 
  PA(P-20:0/22:4); PG(O-20:0/14:1); PG(O-18:0/16:1) 2.27 1.49 3.45 0.0421 
Lysophospholipids LysoPE(20:2) 0.67 0.62 0.72 0.0001 
 
LysoPA(19:3) 2.22 1.69 3.13 0.0090 
 
LysoPC(dm18:1) 1.92 1.56 2.33 0.0100 
 
LysoPC(20:4); LysoPC(18:1) 1.59 1.35 1.85 0.0119 
 
LysoPI(20:4) 2.50 1.85 3.45 0.0265 
 
LysoPC(20:5) 1.59 1.23 2.13 0.0344 
 
LysoPE(20:4) 1.56 1.23 1.96 0.0351 
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   LysoPC(22:5) 0.68 0.55 0.81 0.0424 
Mixed classes Aminoadipate 6-semialdehyde; N-butyrylglycine 0.65 0.52 0.80 0.0396 
Other classes Pantothenic acid 4.00 3.13 5.00 0.0097 
  Ethanolamine 0.63 0.54 0.75 0.0185 
Oxidised fatty acids Hydroxy-hexadecandioic acid (C16:0 double hydroxy) 0.76 0.71 0.82 0.0032 
 
12-keto-tetrahydro-Leukotriene B4; 11-deoxy-PGE1; 11-deoxy-PGF2a 0.45 0.29 0.65 0.0140 
 
Oxo-heneicosanoic acid (C21:0 oxo) 1.52 1.30 1.72 0.0159 
 
Hydroxy-Decenediynoic acid; oxo-decatetraenoic acid (c10 oxo) 0.56 0.42 0.72 0.0291 
 
N-Acetylleukotriene E4; N-acetyl-LTE4 0.58 0.45 0.72 0.0396 
 
Oxo-hydroxy-hexadecadienoate (C16:2 oxy) 1.82 1.52 2.13 0.0400 
 
Prostaglandin E3; prostaglandin D3; 8-iso-15-keto-PGE2 0.83 0.74 0.93 0.0450 
 
Trihydroxy-octadecenoic acid (C18: oxo3) 1.43 1.19 1.67 0.0468 
 
Oxooctadecanoic acid (C18:0 oxy); hydroxyoctadecenoic acid (C18:1 oxy) 1.45 1.15 1.89 0.0472 
 
Hydroxystearate (C18:0 oxy) 1.49 1.20 1.89 0.0481 
  Oxo-tetradecanoic acid (C14 oxo); hydroxy-tetradecenoic acid 1.96 1.35 2.70 0.0500 
Peptides Aspartyl-glutamic acid; N-acetyl-seryl-aspartate 1.61 1.35 1.89 0.0457 
Short chain organic acids Itaconate; Mesaconate; Acetylpyruvate 1.61 1.35 1.89 0.0454 
Steroid metabolism Corticosterone; deoxycortisol 2.44 1.72 3.33 0.0246 
  Androsterone sulfate; dihydrotestosterone sulfate 2.38 1.61 3.85 0.0396 
Sulphated metabolite Indoxyl sulfate 3.57 2.22 8.33 0.0034 
 
3-Sulfodeoxycholic acid 1.56 1.23 1.92 0.0324 
  Tetradecyl sulfate 0.83 0.74 0.93 0.0469 
 
Fold change is obese (Ob) divided by control (Cntrl). Metabolites are listed from most to least significant in each class. In the fold change column, 
metabolites increased in ob/ob relative to ob/- mice are in red, and metabolites decreased in ob/ob relative to ob/- mice are in blue. P values are 
FDR adjusted. The species listed are the potential identifies of each metabolite. Any metabolites that were significantly affected by obesity in the 
naïve comparison (Table 1) were excluded from this list. n = 5-8 animals per group. ADP – adenosine diphosphate, Cer – ceramide, DG – 
Diglyceride, dITP – deoxyinosine triphosphate, GalCer – galactosylceramide, GluCer – glucosylceramide, MG – Monoglyceride, PA – phosphatidic 
acid, PC – phosphatidylcholine, PE – phosphatidylethanolamine, PG – phosphatidylglycerol, PS – phosphatidylserine, SM – sphingomyelin, TG – 
triglyceride, UDP – uridine diphosphate.  
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 Fig. 1. Stroke had differential effects on fatty acid metabolism in obese (ob/ob) 
and control (ob/-) mice. (A) No significant correlation between body weight loss 
from the day of surgery to 24 h post-stroke and ischaemic infarct volume was found. 
(B) Blood glucose was measured in tail vein blood pre-surgery and at 24 h post-
stroke. In naïve animals and at 24 h post-stroke, free fatty acid and glycerol 
concentrations were measured in plasma from cardiac blood (C) and epididymal fat 
homogenates (D). Triglyceride and glycerol measurements were made in liver 
homogenates (E). Data are mean ± s.e.m., n = 10 for naïve, n = 14 for stroke group, 
n = 6 for lesion volume analysis, *P < 0.05 versus control ob/- for same treatment, 
#P < 0.05 versus pre-surgery or naïve for same genotype using  (A) Student’s t-test 
or (B-E) two-way ANOVA with Šídák correction for multiple comparisons. 
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Fig. 2. Obesity differentially affected the expression of the lipolytic enzymes 
HSL and ATGL in epididymal adipose tissue after stroke. Expression of hormone 
sensitive lipase (HSL) (A), serine-563 phosphorylated HSL (B) and adipose 
triglyceride lipase (ATGL) (C) was quantified by western blot in epididymal adipose 
tissue homogenates in naïve control ob/- and obese ob/ob animals, or at 24 h post-
stroke. Data are mean ± s.e.m., n = 10 for naïve and n = 14 for stroke groups, *P < 
0.05 versus control ob/- for same treatment, #P < 0.05 versus naïve for same 
genotype using two-way ANOVA with Šídák correction for multiple comparisons. 
Densitometry values were normalised to β-actin as a loading control. 
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 Fig. 3. Obesity altered the expression of inflammatory mediators and 
adipokines in the plasma and metabolically active organs after stroke. 
Measurements were made in plasma from tail vein blood immediately prior to 
surgery (Pre) and at 24 h post-stroke (A). Measurements were also made in 
epididymal fat pad (B) and liver (C) homogenates taken from naïve animals or at 24 
h post-stroke, and normalised to milligram of total protein as measured by BCA 
assay. Cytokine (IL-6, TNFα, CCL2, CXCL1, G-CSF) concentrations were measured 
by CBA. ICAM-1, adiponectin and resistin concentrations were measured by ELISA. 
Data are mean ± s.e.m., n = 10 for naïve and n = 14 for stroke groups, *P < 0.05 
versus control ob/- for same treatment, #P < 0.05 versus pre-surgery or naïve for 
same genotype using two-way ANOVA with Šídák correction for multiple 
comparisons. N.D. = not detected. 
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Fig. 4. Principal component (PC) analysis plots for metabolomics data generated 
using UHPLC-MS in negative (A) and positive (B) ion modes. Analysis was 
performed on plasma 24 h after stroke or in naïve control (ob/-) and obese (ob/ob) 
mice. n = 5-8 animals per group. QC, quality control. Data on class of metabolites 
presented in Fig. 5. 
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Fig. 5. Obesity affected the metabolic response to stroke. Classification of 
plasma metabolites that were significantly different between control (ob/-) and obese 
(ob/ob) mice in naïve mice (A) and at 24 h post-stroke (B). Any metabolites that were 
significantly affected by obesity in the naïve comparison were excluded from the list 
of metabolites affected by obesity in the 24-h post-stroke comparison. n = 5-8 
animals per group. 
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Fig. 6. A summary of the inflammatory and metabolic changes observed in obese 
ob/ob mice acutely (24 h) after stroke, and how we hypothesise they may be related. 
Black text indicates no significant effect, red text indicates observations of significant 
increases, blue text indicates significant decreases, and purple text indicates both 
significant increases and decreases within this category. We hypothesise that acute 
brain damage caused by hypoxia signals to the liver and adipose tissue either by 
humoral or neuronal routes. This leads to alterations in expression and release of 
inflammatory cytokines, which may impact on the metabolic functions of the liver and 
adipose tissue. For example, pro-inflammatory cytokines can promote lipolysis, and 
promote transport of FFA into the blood. The liver and adipose tissue may also 
release cytokines in the circulation. Membrane lipids found in the blood may be 
partially derived from damaged membranes within the CNS. 
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